InvestorsHub Logo
Followers 12
Posts 476
Boards Moderated 0
Alias Born 06/20/2020

Re: TradingPro post# 322554

Tuesday, 09/08/2020 11:27:58 AM

Tuesday, September 08, 2020 11:27:58 AM

Post# of 403328
I think it's amazing news!

From the "Discussion" session of the article:

Given the importance of the TP53 gene in cancer and the frequency of its mutation, several compounds have been tested with the aim of restoring wt p53 function or of degrading the mutated protein to promote apoptosis. Despite the lack of in vivo experiments, which represents a limitation to the present study, the results suggest that kevetrin may be a promising novel drug for the treatment of AML patients carrying either wt or mutant TP53, with the latter representing an imperative medical need due to its associated dismal prognosis (Fig. 6) (9). A phase I clinical trial evaluating kevetrin activity in advanced solid tumors has been successfully completed, and its results indicate good tolerability and the potential for therapeutic response (NCT01664000) (36,48). The data presented herein provide a rationale for an experimental trial in AML patients, particularly those carrying TP53 mutation, for whom the therapeutic options are currently limited.



It's great that there was no funding received for this research. This is true research. I wonder what the note about "KM" in the "Competing Interests" section means?

On a separate note (sorry to be a downer) I find it sad that this article was published online on August 11th, but we were told about it a month later. I suspect Leo found out about it an hour before we did.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News